RxDoctor Payments Data

Mariola Mjaltaj, MD

Family Medicine · Shenandoah, TXNPI 1225383417

Payments from drug & device makers

$7,502in general payments, 2019–2025

Across 444 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$877
  • AbbVie$750
  • Boehringer Ingelheim$554
  • Amgen$550
  • GSK$397
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$7,488100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,502 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$122,139
Medicare patients
482
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$220,860
JardianceEmpagliflozin79$108,123
EliquisApixaban68$75,350
TrulicityDulaglutide35$43,950
JanuviaSitagliptin Phosphate40$42,316
MounjaroTirzepatide32$38,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$27,219
FarxigaDapagliflozin Propanediol18$25,542
MyrbetriqMirabegron28$25,332
LinzessLinaclotide22$23,141
XareltoRivaroxaban12$19,374
VascepaIcosapent Ethyl21$15,927
Effexor XrVenlafaxine Hcl16$14,518
Breo ElliptaFluticasone/Vilanterol25$12,248
Lidocaine20$7,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,054$220,860164 claims
Boehringer IngelheimJardiance, Spiriva Respimat$554$113,86490 claims
PfizerEliquis, Effexor Xr$220$89,86984 claims
Lilly USA, LLCTrulicity, Mounjaro$877$82,73467 claims
MerckJanuvia$99$42,31640 claims
GSKTrelegy Ellipta, Breo Ellipta$397$39,46761 claims
AbbVieLinzess, Synthroid$750$28,80792 claims
AstraZenecaFarxiga$330$25,54218 claims
Astellas Pharma US IncMyrbetriq$63$25,33228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →